Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Arthritis, Rheumatoid 1

Interventions

Rituximab 130Cyclophosphamide 113Peripheral Blood Stem Cell Transplantation 59fludarabine phosphate 55Etoposide 47Mycophenolic Acid 44Radiotherapy 41Filgrastim 41Tacrolimus 40Whole-Body Irradiation 36Busulfan 34Melphalan 33Cyclosporine 30Cytarabine 29Methotrexate 28sargramostim 27Vincristine 27Antilymphocyte Serum 27Prednisone 26Lenalidomide 23obinutuzumab 22Doxorubicin 22Carmustine 21Bortezomib 20Methylprednisolone 19fludarabine 17Dexamethasone 17Bendamustine Hydrochloride 17ibritumomab tiuxetan 15Cord Blood Stem Cell Transplantation 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Follicular × RC-18 × Clear all
NCT02882087 2019-04-03

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

RemeGen Co., Ltd.

Phase 2 Terminated
60 enrolled
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡